Chronic Obstructive Pulmonary Disease&nbsp;
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. In the United States, the term COPD includes two main conditions&mdash;emphysema and chronic bronchitis. In emphysema, the walls between many of the air sacs are damaged. As a result, the air sacs lose their shape and become floppy.
&nbsp;
Chronic Obstructive Pulmonary Disease Epidemiology Segmentation in the 7MM&nbsp;
<ul>
<li class="ql-align-justify">Diagnosed Prevalent cases of COPD</li>
<li class="ql-align-justify">Gender-specific Diagnosed Prevalent cases of COPD</li>
<li class="ql-align-justify">Age-specific Diagnosed Prevalent cases of COPD</li>
<li class="ql-align-justify">Diagnosed Prevalent Cases of COPD Based on Severity of Airflow</li>
<li class="ql-align-justify">Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History COPD</li>
</ul>
&nbsp;
Chronic Obstructive Pulmonary Disease Epidemiological Insights Observed in the 7MM (2023)
<ul>
<li class="ql-align-justify">The total diagnosed prevalent population of Chronic Obstructive Pulmonary Disease in the 7MM was estimated to be 33 million.</li>
<li class="ql-align-justify">The total diagnosed prevalent population of Chronic Obstructive Pulmonary Disease in the US was found to be&nbsp; 55%, 41% in the EU4 and The UK and, 5% in Japan of the total cases in the 7MM .</li>
<li class="ql-align-justify">The total Gender-specific cases of Chronic Obstructive Pulmonary Disease in the 7MM analyzed that females are more prevalent than males.</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market" target="_blank" rel="noopener noreferrer">Chronic Obstructive Pulmonary Disease Market Insight</a>
The market size of Chronic Obstructive Pulmonary Disease in the 7MM was found to be USD 12.5 bllion in 2023. &nbsp;
&nbsp;
Chronic Obstructive Pulmonary Disease Market Drivers
<ul>
<li class="ql-align-justify">Increasing prevalence of COPD</li>
<li class="ql-align-justify">Emergence in the development of emerging therapies</li>
<li class="ql-align-justify">Personalized treatments</li>
<li class="ql-align-justify">Entry of the &lsquo;Act earlier&rsquo; concept in the market</li>
<li class="ql-align-justify">Improvement in diagnostic techniques</li>
<li class="ql-align-justify">Growing demand for fixed-dose combinations</li>
</ul>
&nbsp;
Chronic Obstructive Pulmonary Disease Market Barriers
&nbsp;
<ul>
<li class="ql-align-justify">Late recognition of COPD</li>
<li class="ql-align-justify">High cost of treatment</li>
<li class="ql-align-justify">Challenges in existing therapies</li>
<li class="ql-align-justify">Patient-related barriers</li>
<li class="ql-align-justify">Drug failure</li>
<li class="ql-align-justify">Availability of generics</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight" target="_blank" rel="noopener noreferrer">Chronic Obstructive Pulmonary Disease Emerging Therapies</a>
&nbsp;
The emerging drugs in the Chronic Obstructive Pulmonary Disease market are
<ul>
<li class="ql-align-justify">Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb)</li>
<li class="ql-align-justify">Dupixent (Dupilumab)</li>
<li class="ql-align-justify">Tyvaso (Inhaled treprostinil solution)</li>
<li class="ql-align-justify">Ensifentrine (RPL554)</li>
<li class="ql-align-justify">Fasenra (Benralizumab)</li>
<li class="ql-align-justify">CHF6001 (Tanimilast)</li>
<li class="ql-align-justify">Nucala (Mepolizumab)</li>
<li class="ql-align-justify">MV130 (Bactek)</li>
<li class="ql-align-justify">MEDI3506</li>
<li class="ql-align-justify">SelK2</li>
<li class="ql-align-justify">Epeleuton (DS102)</li>
<li class="ql-align-justify">NOV-14 (CSJ117)</li>
<li class="ql-align-justify">Zofin</li>
<li class="ql-align-justify">NTHi Mcat investigational vaccine (GSK3277511A)</li>
<li class="ql-align-justify">Icenticaftor (QBW251)</li>
<li class="ql-align-justify">Kalydeco (Ivacaftor/VX-770)</li>
<li class="ql-align-justify">PUL-042 Inhalation Solution</li>
<li class="ql-align-justify">Benlysta (Belimumab)</li>
<li class="ql-align-justify">Azithromycin</li>
<li class="ql-align-justify">Tezepelumab</li>
<li class="ql-align-justify">Acumapimod (BCT-197)</li>
<li class="ql-align-justify">BIO-11006 Inhalation Solution</li>
</ul>
&nbsp;
Chronic Obstructive Pulmonary Disease Key Players&nbsp;
&nbsp;
The key players working in the Chronic Obstructive Pulmonary Disease market are
&nbsp;
<ul>
<li class="ql-align-justify">Sanofi</li>
<li class="ql-align-justify">Regeneron Pharmaceuticals</li>
<li class="ql-align-justify">United Therapeutics</li>
<li class="ql-align-justify">Verona Pharma PLC</li>
<li class="ql-align-justify">AstraZeneca</li>
<li class="ql-align-justify">Chiesi Farmaceutici S.p.A</li>
<li class="ql-align-justify">GlaxoSmithKline</li>
<li class="ql-align-justify">Inmunotek</li>
<li class="ql-align-justify">Tetherex Pharmaceuticals Corporation</li>
<li class="ql-align-justify">Afimmune</li>
<li class="ql-align-justify">Novartis Pharmaceuticals</li>
<li class="ql-align-justify">Organicell Regenerative Medicine</li>
<li class="ql-align-justify">Vertex Pharmaceuticals Incorporated</li>
<li class="ql-align-justify">Pulmotect Inc.</li>
<li class="ql-align-justify">Genentech</li>
<li class="ql-align-justify">Amgen</li>
<li class="ql-align-justify">Mereo BioPharma</li>
<li class="ql-align-justify">Biomarck Pharmaceuticals</li>
</ul>
&nbsp;

Chronic Obstructive Pulmonary (COPD) Disease Infographics

Chronic Obstructive Pulmonary Disease (COPD) Market

Chronic Obstructive Pulmonary Disease Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape